spec sheet11 rows
Decapeptide-12 is a synthetic peptide made of ten amino acids that is used in cosmetic skincare as a skin-brightening agent, best known under the trade name Lumixyl. It works by inhibiting tyrosinase, the enzyme that controls the pace of melanin production, and was developed as a gentler alternative to the traditional lightening agent hydroquinone. Applied to the skin, usually as part of a multi-step brightening routine, it has been studied mainly for melasma and other forms of facial hyperpigmentation. It is regulated as a cosmetic ingredient rather than a drug, and the clinical evidence for it comes from a small number of studies.
- Fades hyperpigmentation and melasma
- Non-hydroquinone option
- Low irritation profile
- Even skin-tone improvement
- Occasional mild skin irritation
Overview
Decapeptide-12 is a proprietary oligopeptide, a short chain of ten amino acids, designed as a topical inhibitor of the pigment-forming enzyme tyrosinase [1]. Its cosmetic ingredient name is decapeptide-12, and it is marketed under the brand Lumixyl. Laboratory testing showed that it competitively inhibits both mushroom and human tyrosinase without the cell toxicity associated with hydroquinone [1].
The peptide was developed by a group led by Basil Hantash at the Elixir Institute of Regenerative Medicine and was commercialized as a skin-brightening product; the stated goal was a non-toxic alternative to hydroquinone for treating hyperpigmentation [1][2]. It is used topically, typically at a concentration around 0.01 percent, and is often supplied as one component of a multi-step brightening system that pairs the peptide cream with an antioxidant cleanser, a glycolic acid lotion, and a sunscreen [2][3].
Clinical evidence is limited and comes largely from small studies by the developers and their collaborators. A split-face, double-blind, placebo-controlled pilot in a handful of patients with recalcitrant melasma reported significant improvement over sixteen weeks with good tolerability [1]; case reports and open-label evaluations of the brightening system described reductions in melasma severity scores over successive weeks of use, including in Hispanic and Asian patients [2][3]; and a later product combining the peptide with additional active ingredients showed further improvement in melasma and photodamage [4]. Because these studies are small and often industry-linked, the overall strength of evidence is modest.
Decapeptide-12 is regulated as a cosmetic ingredient rather than a medicine, so it is not subject to drug approval. It appears in creams, serums, and brightening kits, generally at low concentrations, and is positioned as a well-tolerated option for people seeking to reduce the appearance of uneven pigmentation.
Mechanism
Melanin, the pigment responsible for skin color and for dark patches such as melasma, is produced by melanocytes through a series of reactions in which the enzyme tyrosinase is the rate-limiting step [1]. Decapeptide-12 acts as a competitive inhibitor of tyrosinase, binding the enzyme and slowing the conversion of the amino acid tyrosine into the precursors of melanin, so that less pigment is formed [1]. This differs from hydroquinone, which lightens skin partly by being toxic to melanocytes; the was reported to inhibit tyrosinase without that cytotoxicity, which is the basis for its positioning as a gentler brightening agent [1]. In practice it is used alongside exfoliating and sun-protective measures, since limiting new pigment formation works best when combined with removal of existing pigment and prevention of ultraviolet-driven melanin production [3].
receptor fingerprint
Melanocyte viabilityspares
Tyrosinaseinhibits
Melanocyte pigment outputreduces
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Topical use is generally well tolerated with low irritation compared to hydroquinone. Mild redness or dryness can occur. As with any brightener, daily sunscreen is essential or new sun exposure will undo progress.
Subjective profileweighing the evidence above
A mild, well-tolerated brightener for hyperpigmentation. Works, but slowly, and mostly as part of a routine rather than a standalone fix.
Resources
This entry is here for reference.
Research
- 2009first citedA split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligo…
- 2018most recentEfficacy of Trifecting(®) Night Cream, a Novel Triple acting Skin Brightening Product: A Double…
- 1.A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma
- 2.Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system
- 3.Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma
- 4.Efficacy of Trifecting(®) Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study.
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is decapeptide-12 taken orally or injected?
Neither; it is a topical skincare peptide applied to the skin.
How does it compare to hydroquinone?
It is gentler and does not damage melanocytes, but it works more slowly.
How long until I see fading?
Usually 8 to 16 weeks of consistent use, since it acts on new pigment.
Do I still need sunscreen?
Absolutely; without daily SPF new sun exposure will keep making pigment faster than the peptide can fade it.
Can I combine it with other brighteners?
Yes, it is often layered with vitamin C or niacinamide for a stronger effect.
Adverse effects
- Occasional mild skin irritation
Notes and cautions
- Generally well tolerated in the available studies
- Cosmetic ingredient; effects develop gradually
- Best results reported within a broader routine that includes sun protection